Literature DB >> 25009291

SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Darmood Wei1, Dennis Goldfarb2, Shujie Song3, Courtney Cannon4, Feng Yan5, Donastas Sakellariou-Thompson5, Michael Emanuele4, Michael B Major6, Bernard E Weissman7, Yasumichi Kuwahara8.   

Abstract

UNLABELLED: Malignant rhabdoid tumors (MRT), a pediatric cancer that most frequently appears in the kidney and brain, generally lack SNF5 (SMARCB1/INI1), a subunit of the SWI/SNF chromatin-remodeling complex. Recent studies have established that multiple SWI/SNF complexes exist due to the presence or absence of different complex members. Therefore, the effect of SNF5 loss upon SWI/SNF complex formation was investigated in human MRT cells. MRT cells and primary human tumors exhibited reduced levels of many complex proteins. Furthermore, reexpression of SNF5 increased SWI/SNF complex protein levels without concomitant increases in mRNA. Proteomic analysis, using mass spectrometry, of MRT cells before and after SNF5 reexpression indicated the recruitment of different components into the complex along with the expulsion of others. IP-Western blotting confirmed these results and demonstrated similar changes in other MRT cell lines. Finally, reduced expression of SNF5 in normal human fibroblasts led to altered levels of these same complex members. These data establish that SNF5 loss during MRT development alters the repertoire of available SWI/SNF complexes, generally disrupting those associated with cellular differentiation. These findings support a model where SNF5 inactivation blocks the conversion of growth-promoting SWI/SNF complexes to differentiation-inducing ones. Therefore, restoration of these complexes in tumors cells provides an attractive approach for the treatment of MRTs. IMPLICATIONS: SNF5 loss dramatically alters SWI/SNF complex composition and prevents formation of complexes required for cellular differentiation. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25009291      PMCID: PMC4233162          DOI: 10.1158/1541-7786.MCR-14-0005

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  Activation domain-mediated targeting of the SWI/SNF complex to promoters stimulates transcription from nucleosome arrays.

Authors:  K E Neely; A H Hassan; A E Wallberg; D J Steger; B R Cairns; A P Wright; J L Workman
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

Review 2.  The SWI/SNF complex--chromatin and cancer.

Authors:  Charles W M Roberts; Stuart H Orkin
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.

Authors:  K Xu; H Ma; T J McCown; I M Verma; T Kafri
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

4.  Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression.

Authors:  B E Weissman; P J Saxon; S R Pasquale; G R Jones; A G Geiser; E J Stanbridge
Journal:  Science       Date:  1987-04-10       Impact factor: 47.728

5.  Characterization of ouabain resistant, hypoxanthine phosphoribosyl transferase deficient human cells and their usefulness as a general method for the production of human cell hybrids.

Authors:  B Weissman; E J Stanbridge
Journal:  Cytogenet Cell Genet       Date:  1980

6.  Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.

Authors:  M F Decristofaro; B L Betz; C J Rorie; D N Reisman; W Wang; B E Weissman
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

7.  Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.

Authors:  M F DeCristofaro; B L Betz; W Wang; B E Weissman
Journal:  Oncogene       Date:  1999-12-09       Impact factor: 9.867

8.  Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.

Authors:  Bryan L Betz; Matthew W Strobeck; David N Reisman; Erik S Knudsen; Bernard E Weissman
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

9.  INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells.

Authors:  Britta S Reincke; Gary B Rosson; Betty W Oswald; Cynthia F Wright
Journal:  J Cell Physiol       Date:  2003-03       Impact factor: 6.384

10.  Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes.

Authors:  Diem N Doan; Timothy M Veal; Zhijiang Yan; Weidong Wang; Stephen N Jones; Anthony N Imbalzano
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

View more
  14 in total

1.  Composition and Function of Mutant Swi/Snf Complexes.

Authors:  Arnob Dutta; Mihaela Sardiu; Madelaine Gogol; Joshua Gilmore; Daoyong Zhang; Laurence Florens; Susan M Abmayr; Michael P Washburn; Jerry L Workman
Journal:  Cell Rep       Date:  2017-02-28       Impact factor: 9.423

Review 2.  Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.

Authors:  Matthew J McBride; Cigall Kadoch
Journal:  J Pathol       Date:  2018-03-06       Impact factor: 7.996

3.  Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.

Authors:  Krystal A Orlando; Vinh Nguyen; Jesse R Raab; Tara Walhart; Bernard E Weissman
Journal:  Expert Rev Anticancer Ther       Date:  2019-05-13       Impact factor: 4.512

4.  The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity.

Authors:  Harpreet Kaur; Marianne Hütt-Cabezas; Melanie F Weingart; Jingying Xu; Yasumichi Kuwahara; Anat Erdreich-Epstein; Bernard E Weissman; Charles G Eberhart; Eric H Raabe
Journal:  J Neuropathol Exp Neurol       Date:  2015-02       Impact factor: 3.685

5.  Evaluation of the role of downregulation of SNF5/INI1 core subunit of SWI/SNF complex in clear cell renal cell carcinoma development.

Authors:  Elzbieta Sarnowska; Michal Szymanski; Nataliia Rusetska; Marcin Ligaj; Iga Jancewicz; Pawel Cwiek; Marta Skrodzka; Marcin Leszczynski; Joanna Szarkowska; Alicja Chrzan; Malgorzata Stachowiak; Jaroslaw Steciuk; Anna Maassen; Lech Galek; Tomasz Demkow; Janusz A Siedlecki; Tomasz J Sarnowski
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

6.  Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.

Authors:  Melanie F Weingart; Jacquelyn J Roth; Marianne Hutt-Cabezas; Tracy M Busse; Harpreet Kaur; Antoinette Price; Rachael Maynard; Jeffrey Rubens; Isabella Taylor; Xing-Gang Mao; Jingying Xu; Yasumichi Kuwahara; Sariah J Allen; Anat Erdreich-Epstein; Bernard E Weissman; Brent A Orr; Charles G Eberhart; Jaclyn A Biegel; Eric H Raabe
Journal:  Oncotarget       Date:  2015-02-20

7.  SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.

Authors:  Robert T Nakayama; John L Pulice; Alfredo M Valencia; Matthew J McBride; Zachary M McKenzie; Mark A Gillespie; Wai Lim Ku; Mingxiang Teng; Kairong Cui; Robert T Williams; Seth H Cassel; He Qing; Christian J Widmer; George D Demetri; Rafael A Irizarry; Keji Zhao; Jeffrey A Ranish; Cigall Kadoch
Journal:  Nat Genet       Date:  2017-09-25       Impact factor: 38.330

8.  Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.

Authors:  Pavlos Msaouel; Gabriel G Malouf; Xiaoping Su; Hui Yao; Durga N Tripathi; Melinda Soeung; Jianjun Gao; Priya Rao; Cristian Coarfa; Chad J Creighton; Jean-Philippe Bertocchio; Selvi Kunnimalaiyaan; Asha S Multani; Jorge Blando; Rong He; Daniel D Shapiro; Luigi Perelli; Sanjana Srinivasan; Federica Carbone; Patrick G Pilié; Menuka Karki; Riyad N H Seervai; Bujamin H Vokshi; Dolores Lopez-Terrada; Emily H Cheng; Ximing Tang; Wei Lu; Ignacio I Wistuba; Timothy C Thompson; Irwin Davidson; Virginia Giuliani; Katharina Schlacher; Alessandro Carugo; Timothy P Heffernan; Padmanee Sharma; Jose A Karam; Christopher G Wood; Cheryl L Walker; Giannicola Genovese; Nizar M Tannir
Journal:  Cancer Cell       Date:  2020-04-30       Impact factor: 31.743

Review 9.  Atypical teratoid/rhabdoid tumors: challenges and search for solutions.

Authors:  Ahitagni Biswas; Lakhan Kashyap; Aanchal Kakkar; Chitra Sarkar; Pramod Kumar Julka
Journal:  Cancer Manag Res       Date:  2016-09-16       Impact factor: 3.989

10.  LIN28B is highly expressed in atypical teratoid/rhabdoid tumor (AT/RT) and suppressed through the restoration of SMARCB1.

Authors:  Seung Ah Choi; Seung-Ki Kim; Ji Yeoun Lee; Kyu-Chang Wang; Chanhee Lee; Ji Hoon Phi
Journal:  Cancer Cell Int       Date:  2016-04-18       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.